Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States
Autor: | Andrew Huynh, Robert G. Gish, Khanh K. Nguyen, Robert J. Wong, Huy A. Nguyen, Jenny Yang, My Nguyen, M. T. Ly, Huy N. Trinh, E. da Silveira, Brian S. Levitt, Ruel T. Garcia |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Ledipasvir Adult Male medicine.medical_specialty Sofosbuvir Adolescent Genotype Sustained Virologic Response Hepatitis C virus Hepacivirus medicine.disease_cause Antiviral Agents 03 medical and health sciences chemistry.chemical_compound Young Adult 0302 clinical medicine Virology Internal medicine medicine Humans Aged Retrospective Studies Aged 80 and over Fluorenes Hepatology Asian business.industry Ribavirin Retrospective cohort study Hepatitis C Chronic Middle Aged United States Regimen 030104 developmental biology Infectious Diseases Treatment Outcome chemistry Cohort 030211 gastroenterology & hepatology Benzimidazoles Female business medicine.drug |
Zdroj: | Journal of viral hepatitis. 24(1) |
ISSN: | 1365-2893 |
Popis: | Summary Sofosbuvir/ledipasvir (SOF/LDV) is the first all-oral ribavirin-free treatment approved for chronic hepatitis C virus (HCV) genotype 6, offering a safe and highly efficacious treatment option. Large studies evaluating real-world outcomes of this regimen are lacking. We aim to evaluate real-world treatment outcomes for HCV genotype 6. A retrospective cohort study evaluated 65 adults (age ≥18) with chronic HCV genotype 6 treated with SOF/LDV without ribavirin at a community gastroenterology clinic in the United States from November 2014 to May 2016. Rates of undetectable virus at week 4 on treatment, at end of treatment (EOT) and SVR12 were stratified by the presence of cirrhosis and prior treatment (treatment naive vs treatment experienced). Among 65 patients with chronic HCV genotype 6 treated with SOF/LDV (52.3% male, mean age 66.3 years [SD 9.7], 41.5% cirrhosis and 15.4% treatment experienced), 97.3% had undetectable virus at week 4 on treatment, 96.9% had undetectable virus at EOT and 95.3% achieved SVR12. SVR12 was 100% in females vs 91.2% in males, P=.096, and 92.3% in patients with cirrhosis vs 97.4% in those without cirrhosis, P=.347. Resistance testing of treatment failures was attempted but unsuccessful due to lack of conforming primers to define the possible resistance mutations. Among the largest U.S. community-based real-world cohort of Asian chronic HCV genotype 6 patients treated with all-oral SOF/LDV without ribavirin, SVR12 was similar to SVR12 reported in clinical trials, confirming the safety and effectiveness of this regimen and validating current HCV genotype 6 treatment guideline recommendations. |
Databáze: | OpenAIRE |
Externí odkaz: |